Kazia Therapeutics Announces Presentation of EVT801 Clinical Data at 15th Biennial Ovarian Cancer Research Symposium
Provided By PR Newswire
Last update: Sep 23, 2024
SYDNEY, Sept. 23, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, is pleased to announce the presentation of data highlighting promising clinical activity of EVT801 in high grade serous (HGS) Ovarian Cancer at the 15th Biennial Ovarian Cancer Research Symposium, co-presented by American Association of Cancer Research (AACR) and the Rivkin Center for Ovarian Cancer Research on Saturday, September 21, 2024 in Seattle Washington.
Read more at prnewswire.com1.18
+0.33 (+39.63%)
Find more stocks in the Stock Screener
KZIA Latest News and Analysis
2 days ago - ChartmillWhich stocks are moving after the closing bell on Friday?Discover the top movers in Friday's after-hours session and stay informed about the post-market dynamics.
2 days ago - ChartmillLet's have a look at the top gainers and losers one hour before the close of the markets of today's session.Keep an eye on the top gainers and losers in Friday's session, as they reflect the most notable price movements.
